ES2127178T3 - Forma amorfa de aztreonam. - Google Patents

Forma amorfa de aztreonam.

Info

Publication number
ES2127178T3
ES2127178T3 ES88110480T ES88110480T ES2127178T3 ES 2127178 T3 ES2127178 T3 ES 2127178T3 ES 88110480 T ES88110480 T ES 88110480T ES 88110480 T ES88110480 T ES 88110480T ES 2127178 T3 ES2127178 T3 ES 2127178T3
Authority
ES
Spain
Prior art keywords
aztreonam
amorphic form
amorphic
methylethoxy
ami
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88110480T
Other languages
English (en)
Inventor
Sailesh Amilal Varia
George Eugene Reier
James Douglas Pipkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of ES2127178T3 publication Critical patent/ES2127178T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A LA PREPARACION DE FORMA AMORFA NO-CRISTALINA DEL ACIDO [3S-[3 ALFA (Z), 4 BETA]-3[[2-AMINO-4TIAZOLIL [1-CARBOXI-1-METILETOXI)-IMINO]ACETIL]AMINO]-4METIL-2-OXO-1-AZETIDINOSULFONICO Y DE SUS SALES FARMACEUTICAMENTE.
ES88110480T 1987-07-01 1988-06-30 Forma amorfa de aztreonam. Expired - Lifetime ES2127178T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6839287A 1987-07-01 1987-07-01

Publications (1)

Publication Number Publication Date
ES2127178T3 true ES2127178T3 (es) 1999-04-16

Family

ID=22082279

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88110480T Expired - Lifetime ES2127178T3 (es) 1987-07-01 1988-06-30 Forma amorfa de aztreonam.

Country Status (9)

Country Link
EP (1) EP0297580B1 (es)
JP (1) JP2701869B2 (es)
KR (1) KR890002141A (es)
CN (1) CN1028234C (es)
AT (1) ATE175965T1 (es)
CA (1) CA1339136C (es)
DE (1) DE3856297T2 (es)
ES (1) ES2127178T3 (es)
GR (1) GR3029873T3 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191492B (es) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
JP4646489B2 (ja) 2000-12-27 2011-03-09 ギリアド サイエンシズ， インコーポレイテッド 肺細菌感染症の治療及び予防のための吸入可能なアズトレオナム
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
MXPA05001486A (es) 2002-08-05 2006-05-25 Teva Gyogyszergyar Reszvenytar Preparacion de aztreonam.
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CN1802371A (zh) 2003-05-15 2006-07-12 特瓦药厂有限公司 残余溶剂含量极低的阿兹托南β多晶型
BRPI0411691A (pt) * 2003-07-02 2006-12-26 Teva Gyogyszergyar Reszvenytar l-lisina de aztreonam e seus métodos de preparação
ES2540852T3 (es) 2003-12-25 2015-07-14 Eisai R&D Management Co., Ltd. Cristal de sal de 4-(3-cloro-4-(ciclopropilaminocarbonil)aminofenoxi)-7-metoxi-6-quinolincarboxamida o de su solvato, y procedimientos para producir estos
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
ES2321336T3 (es) 2005-05-09 2009-06-04 Sicor Inc. Procedimiento para la fabricacion de aztreonam.
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
CA2606719C (en) * 2005-06-23 2010-08-10 Eisai R & D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN101579336B (zh) * 2009-07-07 2010-06-23 重庆市庆余堂制药有限公司 一种注射用氨曲南及其生产方法
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CN101912356B (zh) * 2010-08-02 2012-01-11 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN104755463A (zh) * 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1181075A (en) * 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile

Also Published As

Publication number Publication date
KR890002141A (ko) 1989-04-08
JPS6422874A (en) 1989-01-25
CN1030238A (zh) 1989-01-11
JP2701869B2 (ja) 1998-01-21
EP0297580B1 (en) 1999-01-20
CA1339136C (en) 1997-07-29
CN1028234C (zh) 1995-04-19
DE3856297T2 (de) 1999-06-02
DE3856297D1 (de) 1999-03-04
GR3029873T3 (en) 1999-07-30
EP0297580A1 (en) 1989-01-04
ATE175965T1 (de) 1999-02-15

Similar Documents

Publication Publication Date Title
ES2127178T3 (es) Forma amorfa de aztreonam.
CA2418125A1 (en) Beta-lactams useful in the preparation of substituted isoserine esters
CA2333938A1 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
FI103508B1 (fi) Menetelmä anti-inflammatorisen aktiivisuuden omaavien 2-substituoitujen tiatsolidinonien, oksatsolidinonien ja imidatsolidinonien 3,5-di-tert.butyyli-4-hydroksifenyylimetyleenijohdannaisten valmistamiseksi
AU557096B2 (en) Thiazole derivatives
ATE123778T1 (de) Beta-lactam-derivate.
YU117185A (en) Process for obtaining 2-substituted-1,3 propyl of idenediphosphonate derivatives
NO302174B1 (no) Fremgangsmate for fremstilling av metallkomplekser av N-<beta>-hydroksyalkyl-tri-N-karboksyalkyl-1,4,7,10-tetraazasyklododekan- og N-<beta>-hydroksyalkyl-tri-N-karboksyalkyl-1,4,8,11-tetraazasyklotetradekanderivater
DE69017174D1 (de) Substituierte Oxophtalazinyl-Essigsäuren und deren Analogen.
NO912992L (no) 1-aminopropandiol-2,3 med hoey renhet, samt fremgangsmaate for fremstilling av forbindelsen.
NO175101C (no) Analogifremgangsmåte for fremstilling av nye, terapeutisk aktive fluornaftacendioner samt mellomprodukter
ES2051711T3 (es) Procedimiento para preparar 2-oxo-1-(((sulfonil sustituido)amino)-carbonil)-azetidinas.
DK435288A (da) Antianaerobe naphthyridinforbindelser
MY111439A (en) Thymosin alpha 1 derivatives
EP0342423A3 (en) Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics
AU584270B2 (en) Novel derivatives of erythromycylamine
DE69012145D1 (de) Beta-lactamderivate.
FI891866A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten sulfonanilidien valmistamiseksi
SE8705068D0 (sv) Kristallina salter av /3s(z)/-2-///1-(2-amino-4-tiazolyl)-2-//2,2-dimetyl-4-oxo-1-(sulfooxi)-3-azetidinyl/-amino/-2-oxoetyliden/-amino/oxi/ettiksyra
DE59206676D1 (de) Tricyclisches Pyridonderivat
EP0413278A3 (en) Use of xanthine derivatives against peptic ulcers
IT1190660B (it) Composto ad attivita' mucoregolatrice e antitosse,procedimento per la sua preparazione e relative composizioni farmaceutiche
IT1190661B (it) Composto ad attivita' mucoregolatrice e fluidificante,procedimento per la sua preparazione e relative composizioni farmaceutiche
CA1271749C (en) HYDRAZIDE DERIVATIVES OF MONOCYCLIC .BETA.-LACTAMS WITH ANTIBIOTIC PROPERTIES
ES2009936A6 (es) Procedimiento para obtener ciprofloxacina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 297580

Country of ref document: ES